Sanofi (France)
Parent Company
174/180 Avenue de France
Paris
Cedex
75013
France
Tel: 33-1-53-77-4000
Website: http://www.sanofi-synthelabo.fr/
1741 articles with Sanofi (France)
-
The digital-enabled aspect of the manufacturing plant is designed to leverage better use of data to optimize manufacturing processes and increase efficiencies.
-
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
-
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
-
In the wake of the discovery that some Zantac products may contain a carcinogen contaminant due to the manufacturing process, three major drug store retailers in the United States have removed the antacid product from the shelves.
-
Clinical Catch-Up: September 16-20
9/23/2019
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories. -
The deal had the upside potential of $1.7 billion but showed mixed results in three Phase III clinical trials. Sanofi announced it had terminated the collaboration, but Lexicon lashed out, alleging Sanofi’s termination was “invalid” and the company was “in breach of contract.”
-
Glioblastoma is very difficult to treat and there have been several recent clinical trial failures for new drugs.
-
The two companies will seek approval for the biologic as a treatment for severe atopic dermatitis in children ages six to 11.
-
There were a number of major companies reporting their second-quarter financials for the year. Here’s a look at five of the bigger announcements this week.
-
Sanofi reported overall net sales increased by 5.5% for the second quarter, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
-
Sanofi will be responsible for leading the clinical program and funding all studies needed to support the over-the-counter switch in the United States and will also be responsible for the regulatory submissions.
-
Extended Half-Life Prophylaxis Improves Quality of Life in Hemophilia Patients, Study Shows
7/9/2019
The introduction of EHLs allowed hemophilia patients to live a life beyond their disease, with improved quality of life, the study showed. -
Clinical data showed Dupixent reduces nasal polyp size, improves congestion and loss of smell, while reducing the need for surgery and systemic corticosteroids.
-
July looks to be a quiet month for the U.S. Food and Drug Administration (FDA), and it sure looks like the agency is trying to get a lot of work done before the July 4 holiday. Here’s a look at the many approvals scheduled for this week.
-
The intention is to focus its research efforts on cancer, immunology, rare diseases and vaccines. The changes will result in the loss of 466 jobs in the two countries.
-
Google and Sanofi are partnering to set up a new virtual innovation lab with a focus on data technologies and digital health. The goal is to change how Sanofi develops new drugs.
-
Clinical Catch-up for June 10-14
6/17/2019
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look. -
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association's 79th Scientific Sessions in San Francisco this week.
-
A Phase III trial compared Sanofi’s Soliqua/Suliqua to other GLP-1 receptor agonists (GLP-1 RA), with Soliqua showing a superior decrease of average blood sugar level (HbA1c) after 26 weeks.
-
Brandicourt, who has helmed Sanofi since 2015, will retire from his CEO role this fall. Sanofi has a rule that its CEO cannot be over the age of 65.